Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

As these tumor markers always show a decreasing trend for responders within 2–4 weeks compared to the baseline, early introduction of a regimen with anti-VEGF activity, such as atezolizumab plus bevacizumab or LEN, in the non-responder population may be crucial in the clinical practice setting ( Fig. 2 ).

also in 47,180 other papers